RNAi

Arrowhead seeks approval to begin RNAi therapy trial for obesity treatment
Clinical Trials Arena
Wed, 12/4/24 - 10:54 am
Arrowhead Pharmaceuticals
New Zealand
clinical trials
RNAi
ARO-ALK7
obesity
Alnylam cashes in priority review voucher to catch up to BridgeBio in ATTR-CM race
First Word Pharma
Tue, 11/26/24 - 11:04 am
Alnylam
FDA
RNAi
vutrisiran
ATTR-CM
Alnylam reveals trial outcomes of nucresiran for ATTR amyloidosis treatment
Clinical Trials Arena
Mon, 11/18/24 - 06:30 pm
Alnylam Pharmaceuticals
nucresiran
RNAi
clinical trials
An RNAi renaissance is creating a new generation of startups
BioPharma Dive
Wed, 11/6/24 - 11:41 am
RNAi
Alnylam Pharmaceuticals
City Therapeutics
Jude Bio
Switch Therapeutics
Aro Biotherapeutics
Alnylam boots Type 2 diabetes asset from haunted house
Fierce Biotech
Fri, 11/1/24 - 11:09 am
Alnylam
RNAi
type 2 diabetes
Startup led by John Maraganore raises $135M to build ‘future of RNAi’
BioPharma Dive
Tue, 10/8/24 - 09:50 pm
City Therapeutics
funding
RNAi
John Maraganore
Arrowhead Pharmaceuticals seeks approval for obesity treatment trial in New Zealand
Clinical Trials Arena
Tue, 09/24/24 - 11:51 am
Arrowhead Pharmaceuticals
clinical trials
ARO-INHBE
RNAi
obesity
New Zealand
Arrowhead’s RNAi therapeutic plozasiran shows promise in familial chylomicronaemia syndrome
PM Live
Tue, 09/3/24 - 11:23 am
Arrowhead Pharmaceuticals
RNAi
familial chylomicronemia syndrome
plozasiran
After clearing out heart disease drug, Arrowhead maps out obesity development plans
Fierce Biotech
Wed, 08/14/24 - 10:41 pm
Arrowhead Pharmaceuticals
RNAi
R&D
obesity
heart disease
Arrowhead axes heart disease drug, goes all in on another as pipeline progress drives costs up
Fierce Biotech
Wed, 06/26/24 - 10:05 am
Arrowhead Pharmaceuticals
RNAi
zodasiran
plozasiran
cardiovascular disease
Alnylam’s vutrisiran aces ATTR cardiomyopathy readout
Pharmaphorum
Mon, 06/24/24 - 10:52 am
Alnylam
RNAi
vutrisiran
ATTR
cardiomyopathy
Arrowhead's plozasiran could reach $700M-plus in sales by 2032, meet major unmet need in dyslipidemia: GlobalData
Fierce Pharma
Tue, 04/16/24 - 10:05 pm
Arrowhead Pharmaceuticals
clinical trials
RNAi
plozasiran
dyslipidemia
Arrowhead axes assets, but spares staff, to save $100M a year in refocus on core areas
Fierce Biotech
Wed, 02/7/24 - 11:21 am
Arrowhead Pharmaceuticals
RNAi
Novartis dances into JPM with $250M Calypso buyout, $185M RNAi alliance
Fierce Biotech
Mon, 01/8/24 - 11:33 am
Novartis
Calypso
M&A
RNAi
JPMHC 2024
With FDA nod for rare disease drug Rivfloza, Novo Nordisk eyes showdown with Alnylam
Fierce Pharma
Mon, 10/2/23 - 06:36 pm
Novo Nordisk
Rivfloza
FDA
primary hyperoxaluria type 1
RNAi
Alnylam
Roche, Alnylam Ink Potential $2.8B RNAi Partnership for Hypertension
BioSpace
Mon, 07/24/23 - 11:29 am
Roche
Alnylam
RNAi
hypertension
zilebesiran
AAIC: First Clinical Data from an RNAi Therapeutic for Alzheimer’s Continue to Impress
BioSpace
Tue, 07/18/23 - 11:55 am
AAIC
Alnylam
RNAi
Alzheimer's disease
ALN-APP
clinical trials
4DMT provides clinical programme updates for its wet AMD gene therapy
Clinical Trials Arena
Tue, 07/18/23 - 11:40 am
4D Molecular Therapeutics
wet age-related macular degeneration
RNAi
4D-150
Janssen Returns Phase I NASH Candidate to Arrowhead
BioSpace
Wed, 02/15/23 - 06:08 pm
JNJ
Janssen
RNAi
Arrowhead Pharmaceuticals
NASH
Alnylam scraps trial in rare eye disorder, blaming drug price reforms
Pharmaphorum
Fri, 10/28/22 - 10:25 am
Alnylam
RNAi
vutrisiran
Stargardt disease
Inflation Reduction Act
drug pricing

Pages